This official website has .
Sichuan medical institutions in centralized network procurement of additional drugs implementation plan
(Second Revision of 2006)
According to the "Interim Measures for Centralized Bidding and Network Procurement of Drugs for Medical Institutions in Sichuan Province", "Drug Price Differential Rules (Trial)" (National Development and Reform Commission [2005] No. 9), "Drug Price Differential Rules (Trial) of the relevant issues" (Development and Reform Commission [2005] No. 605), the Provincial Price Bureau "Drug Price Differential Rules (Trial)", "Drug Price Differential Rules (Trial) of the relevant issues. (NDRC [2005] No. 9), "Notice on Issues Related to Drug Price Differential Rules (Trial Implementation)" (NDRC [2005] No. 605), "Notice on the Transmittal of NDRC [2005] No. 9 and [2005] No. 605" (Sichuan Price [2005] No. 67), and "Measures for Dynamic Management of Listed Drugs under Centralized Purchasing of Drugs in Sichuan" (Sichuan Pharmaceutical Recruitment Group [2005] No. 10), and other relevant provisions of the documents. No. 10) and other relevant provisions of the document, specially formulated this program.
This program applies to each enterprise to supplement the listed procurement of drugs and all the dynamic adjustment of the listed drugs.
This program is willing to participate in the network of manufacturers of all drugs (including government pricing, government-guided pricing, independent pricing of enterprises) to implement the difference in price rules, the establishment of the maximum procurement limit price.
I. The range of varieties of drugs on the network:
(a) All other dosage forms and generic names not published in the "Sichuan Provincial Medical Institutions on the Internet unlimited drug catalog" are on the Internet price-limiting drugs.
(ii) the original record of Class A drug list of drugs transferred to the Internet price-limiting drugs.
Note: 1. The medicines and dosage forms published in the "Sichuan Provincial Medical Institutions Online Unrestricted Price Drug Catalog" do not belong to the scope of additional online price-restricted drugs.
2. Drugs that have been purchased online shall not be declared again.
3. Drugs in the original filed Class A Drug Catalog that have been converted to online price-limiting drugs and have not been online after the end of this work will not be allowed to be purchased by medical institutions again.
4, special requirements see each supplement announcement
Two, the principles of classification of drugs on the network
(a) the same chemical composition of the drugs on the network, naming the acid root, salt base and solvent is different, categorized as the same kind of drugs; the national standard of the official name of the dosage form of the former part of the same name and national standards of the prescription of the same pCm preparation, categorized as the same kind of drugs (prescription of the same official name, the same). Drugs (prescription of the same official name is different, also categorized as the same kind of drugs).
(2) the quality level of listed drugs:
The drugs are divided into two quality levels.
The first quality level includes: the National Development and Reform Commission (Planning Commission) documents separately priced drugs, the National Development and Reform Commission (Planning Commission) documents the original research drugs, the National Development and Reform Commission (Planning Commission) documents the quality of high-quality and high-priced proprietary Chinese medicines, with the People's Republic of China **** and the State invention patent certificate of patented drugs, respectively, to form the highest procurement limit price listed;
The patent medicines of this program include : chemical drugs with Chinese people's *** and national invention patent certificate structure patents, proprietary Chinese medicines with extract patents or patents on drug compositions. Only the design, utility model or process, efficacy and other patented drugs, is not considered to be the patent drugs referred to in this program.
A structural patent for a chemical drug means that there should be key characterizations such as the name, structure or molecular formula of the compound in its patent document, and the object of protection is the compound itself.
The natural substance extract patent of a proprietary Chinese medicine refers to the protection patent of a substance isolated or extracted from nature for the first time, and the structure, form or other physicochemical parameters of the substance should be precisely represented in its patent document.
A patent for a pharmaceutical composition of a proprietary Chinese medicine is a patent for the protection of a composition of two or more pharmaceutical ingredients, which shall have key expressions of compositional characteristics such as component or content in its patent document, and shall be clearly expressed as a patent for a composition in the patent name, abstract, and claims.
The second quality level includes: domestically produced GMP drugs and imported GMP drugs (including imported/imported sub-packaged drugs), respectively, to form the highest procurement limit price listing.
Third, the principle of determining the representative product
According to the National Development and Reform Commission, "Drug Differential Pricing Rules (Trial)", "Drug Differential Pricing Rules (Trial) Notice of Relevant Issues," the requirements of the determination of the representative product of the listed drugs.
(a) the province's representative of the net procurement of drugs temporarily by the first batch of 2005, the first batch of net drugs limit price, the second and third batch of net drugs representative of the net and the total net results according to the principle of selecting the price of the low development. The province does not have representative products according to the country has announced representative products implementation.
(b) the original class A record of drugs in the catalog of drugs to the Internet price limit, select the medical institutions reported the actual purchase price of the average price of the low price as the price of representative products.
(3) If it is not possible to determine the representative product according to the above principles, the lowest discounted price of the retail price under the same quality level will be selected as the representative product. The discount price of each quality level shall be determined as follows:
1. Originally developed and patented medicines, the first and second types of new medicines of proprietary Chinese medicines shall be priced at 75% of the retail price;
2. The first and second types of new medicines of chemical medicines (within the protection period), medicines with foreign chemical medicine structural patent certificates but have not been granted with China's structural patents and are in the validity period, medicines with domestic notarization and generic exclusive names shall be priced at their retail prices. Exclusive name of the drug is priced at 70 deductions from its retail price;
3, other categories of GMP drugs (including domestic GMP drugs, imported GMP drugs, individually priced drugs, high-quality and high-priced drugs) is priced at 60 deductions from its retail price.
Fourth, the formation of the maximum procurement limit price of listed drugs:
Based on the price of the representative product, the enterprise will be declared the same generic name, the same quality level of other dosage forms, specifications, packaging of the drug, according to the national difference than the price of the relevant documents and [the formation of the maximum procurement limit price of the enterprise declared drug rules] to calculate the corresponding maximum procurement limit price.
(1) The same manufacturer and the same dosage form and specification of drugs can only be declared by one declarant, and when there are two declarations, the one with the lower declared price shall prevail.
(ii) All drugs from manufacturers who agree to the maximum procurement limit price under the same generic name, dosage form, quality level and specification can be listed.
(3) declared that enterprises in the information confirmation in accordance with the price of the network shall not be higher than the maximum purchase price of the principle of price confirmation, where not to accept the maximum purchase price of varieties shall not be included in the health care institutions listed in the drug procurement catalog.
(4) Where the newly declared drugs belonging to the first batch of 2005 on-line procurement of dynamically adjusted catalog, if there is a dynamic adjustment of the price, and the limit price calculated on behalf of the product is higher than the dynamic adjustment of the price, the dynamic adjustment of the price of the maximum procurement limit.
[General Principles]
1. The dosage forms of listed drugs are divided into ordinary tablets, enteric-coated tablets, dispersible tablets, controlled-release tablets, extended-release tablets, ordinary capsules, enteric-coated capsules, granules (granules/punch), oral solutions (composites, gels, colloidal solutions, oral solutions), oral dry suspensions, oral suspensions (suspension drops, suspension mixes), chewable tablets, honey pills (including small honey pills), water honey pills, water pills, concentrated pills, syrup and other classifications, of which the Chinese medicine tablets are divided into sugar-coated tablets, plain tablets, film-coated tablets, and the Chinese medicine capsules include hard capsules and soft capsules; chemical tablets are not divided into plain tablets, sugar-coated tablets, film-coated tablets, and the capsules are not divided into hard capsules and soft capsules.
The dosage forms not listed above are determined according to the approved dosage forms in the production approval.
2. Injectables are categorized according to injection solution, common powder injection, lyophilized powder injection, solvent powder injection, and large-volume injection.
The nature of the drug such as powder injection, solvent crystals, lyophilized powder, in accordance with the drug production approval or instructions or quality standards or the National Development and Reform Commission documents to determine. Production approvals, approved by the national drug regulatory department of the instructions, quality standards in the drug properties must be clearly expressed as lyophilized block (lyophilized or lyophilized powder) or solvent crystallization, or marked as freeze-dried sterile products, sterile lyophilized products, etc., in order to determine the lyophilized or solvent crystallization preparations, and other cases if expressed as a white powder or crystalline powder and so on will always be judged to be a common powder injection. National Development and Reform Commission documents indicating the manufacturer of the drug and drug properties can be recognized.
3, each drug of different specifications, different dosage forms, different quality levels according to the rules of differential price of drugs to form the maximum purchase price.
4, the grid program using the dosage form difference than the price, refers to the same kind of drugs in the unit content of the same premise, the difference between the price of different dosage forms or ratio. No identification of the active ingredient content of proprietary Chinese medicine dosage form, to the same number of daily dose as the premise of the calculation of dosage form differential price. Commonly used dosage form price differentials are shown in the attached table.
Table of Dosage Form Differentials for Commonly Used Western Medicines
Name Category No. Calculation Unit Differential Calculation Formula Difference or Ratio Description
Tablet Ordinary Tablet (1) ---- per tablet 1 No separate distinction is made between plain tablets, sugar-coated or Film-coated
Enteric-coated tablets (2) (2)÷(1) 1.1
Dispersible tablets (3) (3)÷(1) 1.3
Capsule preparations Ordinary hard capsules (4) (4)-(1) $0.02 per capsule Differential with tablets is not taken into account when the price of each capsule is more than $1
Enteric-coated capsules (5) Per capsule (5)÷(4) 1.1
Granules and solutions Granules (soluble, suspension) (6) Per bag (6)÷(1) 1.2
Oral solutions (7) Per stick (7)÷(6) 0.9
Orals dry suspension (8) Per vial (8)÷(6) 1.3
Injections Small-volume injectable solution (9) Sticks (less than 10 ml. ) ---- 1
Large-volume injection (10) Per bottle (100ml) (10)-(9) $5
Differential Price Ratio Table for Commonly Used Dosage Forms of Proprietary Chinese Medicines
Name Category No. Calculation Unit Difference or Ratio Price Calculation Formula Difference or Comparison Value Description
Pills Honey pills (small honey pills) (1) Average daily dosage ---- 1
Water honey pills (2) Average daily dosage (2)÷(1) 1.2
Water pills (3) ) Average daily dose (3)÷(1) 1.3
Concentrated pills (4) Average daily dose (4)÷(1) 1.4
Tablets Sugar-coated tablets (5) Average daily dose ---- 1
Vegetarian tablets ( 6) Average daily dose (6)÷(5) 0.9
Film-coated tablets (7) Average daily dose (7)÷(5) 1.1
Capsules Hard capsules (8) Average daily dose (8)-(5) $0.02 (per capsule) Difference from tablets is not taken into account when the unit price of each capsule is greater than 1 yuan.
Softgels (9) Average daily dose (9)÷(8) 1.5
Pellets and solutions Pellets (10) Average daily dose (10)÷(5) 1.25 Sugar-free can be increased by 10% compared to sugar-containing type
Combinations (oral solutions) (11) Average daily dose (11)÷(10) 0.9
Syrups (12) Average daily intake (12)÷(10) 0.8
5, the listing program using specifications difference ratio, refers to the same type of drugs in the same dosage form due to the specifications (including content, loading, weight, number of packages, or drug traits, etc.) different price difference or ratio.
The content referred to in these rules, refers to a pharmaceutical preparation contains the number of national standards for the number of active ingredients; referred to as the amount, refers to the unit container of the capacity of pharmaceutical preparations; referred to as the weight, refers to the weight of the smallest unit of measurement of the drug; referred to as the number of packages, refers to the number of retail packages contained in the smallest unit of measurement of the pharmaceutical preparation; retail packaging refers to the smallest retail packaging (excluding hospital pharmacies sold in odd lots), the price difference or ratio. include packages split for sale in hospital inpatient pharmacies).
6. Injections with content labeling, solution (dosage) loading of 10ml (including 10ml) or less, according to the main drug content statistics, the price is not differentiated; 10ml or more, solution (dosage) loading of every increase (decrease) of 10ml, the price of plus (minus) 0.05 yuan.
7, in other conditions are the same, the injection of ordinary powder injection in small water injection price based on each additional 1 yuan, lyophilized powder injection, solvent powder injection price in small water injection price based on each additional 3 yuan (pCm injections are not applicable for the time being).
8, small-volume injections in the price does not distinguish between the type of container and material differences; large-volume injection prices, based on the same capacity specifications of the price of glass bottles, plastic bottles, plus 2 yuan, and soft bags, plus 4 yuan.
9, boxed (refers to the inner packaging for the plate) oral solid preparations, the price does not distinguish between packaging materials differences; bottled oral solid and liquid preparations, the price does not distinguish between the type of container and material differences; granules in the price does not distinguish between the differences in the bag material.
10, different specifications of the difference between the price of drugs, based on the price of representative products, other conditions are the same, the content increased by 1 times (or reduced by 50%), the price of the corresponding multiplied (or divided) by 1.7.
11, the difference between the price of drugs of different loads or weights, based on the price of representative products, other conditions are the same, the load or the weight of the same increase by 1 times (or reduced by 50%), the price of the corresponding multiplied (or divided) by 1.7.
The formula for calculating the differential price of a non-integer multiple of the loading (weight) is: (K = specific value, X = loading or weight of the product to be determined ÷ loading or weight of the product on behalf of the specifications).
12, specifications of the difference in the number of packages in the difference in price relations
The representative of the price as the basis, other conditions are the same, the number of packages increased by a factor of 1 (or reduced by 50%), the price of the corresponding multiplied (or divided) by 1.95.
Non-integer multiples of the relationship between the number of packages in the difference in the price ratio formula: (K = the ratio of the value of the number of packages of the product ÷ representative of the number of packages of the product specification). the number of packages of the representative specification item).
13, when calculating the differential price of drugs, according to the first dosage form (drug properties) and then content, loading, weight, packaging quantity, packaging materials process.
[Enterprises to declare the formation of the maximum purchase price limit drug rules]
1, the same generic name, the same quality level of the existence of large and small packages of drugs, divided into greater than or equal to 100 pills and less than 100 pills according to their respective representative of the product to limit the price of large packages shall not be higher than the price of small packages, but with the same specifications of small packages of representative of the product of the smallest use of the unit of the price of the product is higher than the price of a large package of representative of the product. The magnitude of the control within 20%.
2, different routes of administration of proprietary Chinese medicine injections, respectively, according to their respective representative product price limits.
3, oral liquid, granules, respectively, according to their respective representative products to limit the price.
4, the same generic name, the same specifications and the same dosage form of drugs, domestic varieties of the maximum procurement limit price shall not be higher than the imported varieties of the maximum procurement limit price.
5. The maximum purchase price of individually priced drugs shall not be higher than the maximum purchase price of originator drugs or patented drugs with the same dosage form and the same specifications.
6, the content of the injection, solution (dosage) loading in 10ml (including 10ml) or less, according to the content of the main drug statistics, the price is not differentiated; less than 50ml of the same content of the injection on behalf of the product loading based on the amount of solution (dosage) loading of each increase (minus) 10ml, the price of plus (minus) 0.05 yuan, the incremental (minus) less than the tail end of the amount of 10ml rounded off; greater than or equal to 50ml and less than 100ml of injection. Equal to 50 ml and less than 100 ml of large-volume injection, first with the representative of the product loading based on a comparison of the price should be equal to the representative of the product price plus 100 ml of the dosage form differential price of 5 yuan, and then according to the actual loading volume of each minus 10 ml of the price minus 0.05 yuan. Large-volume injection is equal to or more than 100 ml, first with the representative of the product loading based on a comparison of the price should be equal to the representative of the product price plus 100 ml of the dosage form differential price of 5 yuan, and then according to the actual loading volume of the price of each increase of 10 ml plus 0.05 yuan. Different content of small injections and large-volume injections according to the first content after the loading of the order of arithmetic calculation.
7, in other conditions are the same, the injection of ordinary powder in small water injection price based on each additional 1 yuan, lyophilized powder, solvent powder injection price in small water injection price based on each additional 3 yuan, can not provide the injection of the drug properties of the ordinary powder (except for injections, pCms injections are not applicable) processing.
8, on the injection of both trait differences and other specifications and packaging materials differences in non-representative products, should be in the representative of the price of the first plus (minus) the amount of trait difference, and then calculated on the basis of other specifications, packaging materials, the difference between the price.
9, and representative of the same dosage form but different specifications, packaging materials, non-representative products, should be in accordance with the content, loading (weight), packaging quantities and packaging materials in the order of the calculation of prices.
10, the following dosage forms, with the content of the main drug by the specifications of the difference in price, without the content of the difference in price according to the volume of the load: injections, tinctures, eye drops, syrups, oral solutions, oral suspensions, oral emulsions, ear drops, nose drops, lotions, rinses, enemas, paints and other pharmaceutical dosage forms with the volume.
11, the following dosage forms, with the content of the main drug by the specifications of the difference in price, without the content of the weight of the difference in price: soft (milk) creams, pastes, eye ointments, dispersions, gels and other pharmaceutical dosage forms of weight.
12, controlled-release tablets, extended-release tablets, aerosols, sprays, suppositories, emulsions, gels, eye drops, ear drops and other unlisted dosage forms are not implemented for the time being the form of the difference in price, but the implementation of the specifications of the difference in price (including the content, loading, weight, number of packages, or the drug properties).
13, pCms injections with labeled volume according to the labeled volume to do the differential price, no labeled volume only loaded, according to the loaded volume to do the differential price calculation.
14, structure of patented drugs, the original development of drugs between different dosage specifications, should be in accordance with the 〈〈Rules〉〉 implementation of the dosage specification difference in price (including content, loading, weight, number of packages, or drug properties).
15, the same enterprise produces a separate pricing drugs, high-quality and high-priced drugs of the same dosage form of different specifications, according to the 〈〈Rules〉, the implementation of the specifications of the difference than the price (including content, loading, weight, number of packages, or the drug traits).
16, chemical particles only the main drug content of the difference in price, not weight difference in price.
17, children's preparations of proprietary Chinese medicines do not use the daily dose of conversion relationship, with the amount of filling or packaging for the difference in price calculation.
18. When there are multiple dosages of proprietary Chinese medicines, the first dosage listed in the instruction manual will be used as the basis for calculation.
19. The granules of proprietary Chinese medicines are divided into sugared and unsweetened types, and the unsweetened or unsweetened types are not labeled, so they are treated as sugared types.
20, where the identification of the active ingredient content of pCms, the use of dosage forms, specifications or packaging materials, the implementation of the difference in price, without the identification of the active ingredient content of the pCm dosage forms to the same daily intake of the prerequisite for the calculation of the difference in the price of the average daily intake of the calculation is as follows:
Example: 2g (pills, granules)-5g (pills, granules)/times, 3-4 times a day, the average daily intake = (2×3+5×4)/2, average daily intake = (2×3+5×4)/2. 3+5×4)/2=13 g.
V. Procedures for declaration of listed medicines and qualification documents to be submitted by enterprises
(1) Procedures for declaration of listed medicines
1. According to the scope of the list of listed catalogs, the declaration is made by the lawful medicine manufacturers or the medicine business enterprises entrusted by the medicine manufacturers;
2. The declarant will declare in the website designated by the handling organization. website (www.scwst.gov.cn Sichuan Drug Purchase Transaction Supervision and Administration Platform) to become a registered user. Fill in the basic information: the name of the authorized person, the name of the declaring enterprise (fill in the full name according to the license of the operating enterprise or the license of the manufacturing enterprise), the office telephone, cell phone, e-mail, fax, user name and password, and so on. After the successful registration of the filer, the system generates the filer's serial number according to the user registration, please declare the enterprise to keep their respective declaration serial number. After the successful declaration by the enterprise, the declarant can log in the platform to fill in the report by himself. Within the specified time and scope, the filer can modify and delete the data, and the enterprise can also print out the completed drug information online. When sending the paper information, the filer will confirm the filled data, and the filer will sign to confirm the data after the listing data is sorted out (for details, please refer to the operation manual).
3. The filer must submit the paper information consistent with the online report to the agency within the specified time. Failure to submit the paper documents within the specified time is considered as an ineligible drug. In case of inconsistency in the submission of paper information, the one provided first shall prevail.
4. Filers are required to visit the website of the Agency on a regular basis to supplement the information as announced or notified by phone.
5. The filer makes the information determination and confirms the price according to the maximum procurement limit price published online.
6. Payment of computerized information processing fees for listed drugs as required.
7, the listing of drugs accepted online, but does not accept the mailing of paper information.
(B) the filer should submit the qualification documents include:
1, the drug manufacturer involved in the listing of the power of attorney (this annex, if the pages, please stamp each page); (submit the original, please keep a copy)
2, product documentation (production approvals, imported drugs, or pharmaceutical product registration certificate or registration certificate of imported sub-packaging approvals) (copy) Please provide the original and copy if it is not available in the database of the State Drug Administration)
3, the authorization letter of the first-class agent of the imported drugs to the drug business enterprises (submit the original, please keep a copy)
4, the first-class agent of the imported drugs is authorized to authorize the power of attorney (the format of the attachment can be changed, but it must state the affiliation of the two sides);
5, the latest Valid price publicity documents of the price authorities in Sichuan Province;
6, for large-volume injections (50ml and above), where the soft bags and plastic bottles for packaging to the instructions or production approvals shall prevail.
7, on the drug properties such as powdered injections, solvent crystals, lyophilized powdered needles, in accordance with the drug production approvals or specifications or quality standards or the National Development and Reform Commission documents to determine. Production approvals, approved by the State Drug Administration department instructions, quality standards in the drug properties must be clearly expressed as lyophilized block or solvent crystallization, or marked as freeze-dried sterile products, sterile lyophilized products, in order to determine the lyophilized or solvent crystallization preparations, other than if expressed as a white powder or crystalline powder, etc. are judged to be the case of the ordinary powder injection. National Development and Reform Commission documents indicating the manufacturer of the drug and drug properties can be recognized.
8, approved by the State Drug Administration of the original drug instructions.
9. One copy each of the paper and electronic version (filled out online) of the audit form of the listed drug information (the format shall be based on the online publication).
10, a copy of the drug manufacturer qualification materials (drug production license, business license of the enterprise). If the drug production license in the State Drug Administration database can not be queried, please provide the original and a copy
11, GMP certificate copy (in the State Drug Administration database can not be queried, please provide the original and a copy; over the expiry date, but has been certified waiting for the issuance of certificates to provide the provincial drug supervision department of the supporting materials or the State Drug Administration Web site publicity documents)
12, original research
12, the original research, individually priced drugs, quality and price of proprietary Chinese medicines to provide a copy of the National Development and Reform Commission (Planning Commission) documents.
13, patented drugs: including the People's Republic of China **** and the country's patent certificate of invention of the structure of chemical patents, patents of extracts of proprietary Chinese medicines and patents of pharmaceutical compositions (see the "implementation of the program" for the specific requirements of the division).
Enterprises are required to submit:
(1) the original and a copy of the patent certificate of the invention of the drug;
(2) the original and a copy of the patent fee for the last year of the patent for the invention;
(3) a copy of the patent publication of the patent for the invention (specification of patent for the invention, claims and abstract).
Pharmaceuticals that have foreign chemical structure patent certificates but have not been granted Chinese structure patents and are within the validity period shall be submitted with reference to the above requirements and shall also be provided with domestic notarization;
14. For new drugs belonging to the first or second category, a copy of the new drug certificate shall be submitted.
15. A copy of the quality standard of the drug specified in the drug production approval.
Note: (1) all the submitted information on each page of the drug manufacturer (imported drugs a agent) and the declarant's seal (official seal, bidding seal is invalid), entrusted to the drug business enterprises to submit the information should be submitted to the drug manufacturer listed on the network of power of attorney or imported drugs a agent of the authorization of the drug business enterprises (the original), the imported drugs a representative of the authorization of the power of attorney.
(2) The Agency will only check the surface authenticity of any supporting materials submitted by the enterprises. If the enterprise is false, any legal responsibility arising from this shall be borne entirely by the submitter and will be dealt with in accordance with the relevant provisions.
(C) in the specified time can not provide relevant documents, audit failed enterprises, listing price higher than the maximum price of the listing, its varieties can not be listed as a drug. Provide false supporting documents, the agency found and confirmed that its varieties can not be listed as a drug, medical institutions at any time to confirm that the declarant in the process of listing and performance of serious violations of the law, the right to submit to the competent administrative department for investigation and handling, and in accordance with the relevant provisions of the treatment.
Sixth, the distribution of listed drugs
(a) the manufacturers of listed drugs (imported drugs first-class agents) must be to the province's all tenders or follow the bidding of medical institutions in accordance with not higher than the listed limit price organization and distribution, or else dealt with in accordance with the relevant provisions.
(2) the production of listed drugs (imported drugs first-class agents) to submit a list of reference distribution enterprises, the distribution of listed drugs by the medical institutions themselves with legitimate drug manufacturers, drug companies to negotiate a solution. Medical institutions should review the legitimacy of the qualifications of distribution enterprises in accordance with the relevant provisions of the Drug Administration Law when selecting distribution enterprises for on-line drugs.
(3) Whether or not the medical institution and the distributing pharmaceutical business enterprise sign the relevant contract shall be decided through consultation between the two parties.
(4) the receipt of listed drug purchases, returns and exchanges, and other issues are implemented in accordance with the relevant provisions of the bidding documents, payback in accordance with the "on further standardizing the centralized bidding and procurement of medicines for medical institutions," (Health Regulation and Finance [2004] No. 320), the people's government at or above the municipal (prefectural) level, the state-owned enterprises (including state-owned enterprises) and other nonprofit health care institutions, the return of medicines Time from the date of arrival of the goods shall not exceed 60 days at the longest, the payback time of other medical institutions should be within the fourth month to pay the first month received by the winning bidder distribution and sold drugs, and then month by month settlement.
VII. Purchase and Use of Listed Drugs
(1) The medical institutions will choose to purchase the listed drugs on the Sichuan Provincial Drug Purchase and Procurement Trading Platform on their own.
(2) The listed price of the listed drugs to implement the price limit, the medical institutions shall not exceed the maximum purchase price of the listed purchase limit.
(C) the procurement of listed drugs by the medical institutions on a regular basis in the Sichuan Provincial Drug Bidding and Purchasing Supervision Platform online, to accept social supervision.
(d) Medical institutions using the same generic name of the drugs in the listed catalog can only be procured from the listed drugs, and may not procure drugs other than the listed drugs.
(v) The proportion of the procurement amount of listed drugs in medical institutions to the total procurement amount of all drugs shall be assessed according to the sunshine procurement management method.
Eight, hanging drug information processing fees
(a), in order to ensure that the normal work of hanging drugs, the successful listing of drugs in accordance with the provisions of the provincial pricing department (Chuan price letter [2006] No. 212), each specimen of a computer information processing fee of 180 yuan, the time and place of the charge will be notified.
(ii) the cities and states do not charge any fees for the drugs listed on the network.
(C) the service fee collected for the province's centralized drug listing work and its subsequent management of the financial expenses.
Nine, the retail price of the networked drugs
(a) The retail price of the networked drugs in accordance with the Sichuan Price Development [2006] No. 152 document, according to the enterprise to confirm the limit of the price of Shunjia 15% (more than 500 yuan of anti-tumor drugs plus 75 yuan) approved the temporary retail price, and reported to the competent department of the price for approval.
(2) The temporary retail price of the listed drugs shall not be higher than the retail price announced to the society by the provincial price authorities.
(3) Medical institutions shall not sell listed drugs above the retail price of listed drugs.
X. Website and Organization of Listed Drugs
(1) The implementation plan of listed drugs, information review results and other relevant information published, procurement transactions announced on the website of the Sichuan Provincial Department of Health: www.scwst.gov.cn
(2) The listing of drugs by the Sichuan Provincial Drug Centralized Bidding and Purchasing Leadership Group organization.
Eleven, the supervision of the procurement of listed drugs
Sichuan Province, the centralized bidding procurement of drugs listed by the Sichuan Provincial Drug Purchase Transaction Supervision and Administration Center supervision.